CONTROLLING STOCKHOLDERS AGREEMENTControlling Stockholders Agreement • February 22nd, 2005 • CardioVascular BioTherapeutics, Inc. • Pharmaceutical preparations • Nevada
This Controlling Stockholders Agreement (the “Agreement”), dated as of August [30], 2004, by and among each of the holders of CardioVascular BioTherapeutics, Inc. Common Stock (“Common Stock”) of CardioVascular BioTherapeutics, Inc., a Delaware corporation (“Cardio”), listed on the signature page hereof and on Schedule A, annexed hereto (each a “Stockholder” and, collectively, the “Stockholders”).
AMENDMENT NO. 1 TO CONTROLLING STOCKHOLDERS AGREEMENTControlling Stockholders Agreement • May 26th, 2006 • CardioVascular BioTherapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 to Controlling Stockholders Agreement (“First Amendment”) is dated as of April 13, 2006, by and among each of the holders of common stock (“common stock”) of CardioVascular BioTherapeutics, Inc., a Delaware corporation (“Cardio”), listed below as signatories hereof (each a “Stockholder” and collectively, the “Stockholders”).
CONTROLLING STOCKHOLDERS’ AGREEMENTControlling Stockholders’ Agreement • December 11th, 2018 • Organogenesis Holdings Inc. • Pharmaceutical preparations • Delaware
THIS CONTROLLING STOCKHOLDERS’ AGREEMENT (the “Agreement”), dated as of December 10, 2018, by and among Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and the holders of common stock, par value $0.001 per share (“Common Stock”), of the Company listed on the signature page hereof and on Schedule A, annexed hereto (each a “Stockholder” and, collectively, the “Stockholders”).
CONTROLLING STOCKHOLDERS AGREEMENTControlling Stockholders Agreement • November 10th, 2005 • Phage Biotechnology CORP • Nevada
This Controlling Stockholders Agreement (the “Agreement”), dated as of November 29, 2005, by and among each of the holders of Phage Biotechnology Corp. Common Stock (“Common Stock”) of Phage Biotechnology Corp., a Delaware corporation (“Phage”), listed on the signature page hereof and on Schedule A, annexed hereto (each a “Stockholder” and, collectively, the “Stockholders”).
